methyl 3-((5-(4-fluorophenylcarbamoyl)pyridin-2-ylthio)methyl)benzoate | 1240494-33-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 3-((5-(4-fluorophenylcarbamoyl)pyridin-2-ylthio)methyl)benzoate
• 英文别名: Methyl 3-[[5-[(4-fluorophenyl)carbamoyl]pyridin-2-yl]sulfanylmethyl]benzoate
• CAS: 1240494-33-0
• 化学式: C₂₁H₁₇FN₂O₃S
• 分子量: 396.442
• InChiKey: YNYGQEFOUZFCIG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  93.6
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  methyl 3-((5-(4-fluorophenylcarbamoyl)pyridin-2-ylthio)methyl)benzoate 在 甲醇 、 sodium hydroxide 、 盐酸 作用下， 以 甲醇 、 水 为溶剂， 反应 1.0h， 以83%的产率得到3-((5-(4-fluorophenylcarbamoyl)pyridin-2-ylthio)methyl)benzoic acid
  参考文献：
  名称：

  Pyridine- and Pyrimidinecarboxamides as CXCR2 Modulators

  摘要：

  披露了作为药物剂的吡啶和嘧啶羧酰胺化合物，合成过程以及包括吡啶和嘧啶羧酰胺化合物的药物组合物。更具体地，披露了一类CXCR2抑制剂化合物，可用于治疗各种炎症和肿瘤性疾病。

  公开号：

  US20100210593A1
• 作为产物：
  描述：

  6-巯基烟酸 在 2-乙氧基-1-乙氧碳酰基-1,2-二氢喹啉 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 methyl 3-((5-(4-fluorophenylcarbamoyl)pyridin-2-ylthio)methyl)benzoate
  参考文献：
  名称：

  Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2

  摘要：

  The G protein-coupled chemokine receptors CXCR1 and CXCR2 play key roles in inflammatory diseases and carcinogenesis. In inflammation, they activate and recruit polymorphonuclear cells (PMNs) through binding of the chemokines CXCL1 (CXCR1) and CXCL8 (CXCR1 and CXCR2). Structure-activity studies that examined the effect of a novel series of S-substituted 6-mercapto-N-phenyl-nicotinamides on CXCL1-stimulated Ca2+ flux in whole human PMNs led to the discovery of 2-[5-(4-fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic acid (SX-517), a potent noncompetitive boronic acid CXCR1/2 antagonist. SX-517 inhibited CXCL1-induced Ca2+ flux (IC50 = 38 nM) in human PMNs but had no effect on the Ca2+ flux induced by C5a, fMLF, or PAF. In recombinant HEK293 cells that stably expressed CXCR2, SX-517 antagonized CXCL8-induced [S-35]GTP?S binding (IC50 = 60 nM) and ERK1/2 phosphorylation. Inhibition was noncompetitive, with SX-517 unable to compete the binding of [I-125]-CXCL8 to CXCR2 membranes. SX-517 (0.2 mg/kg iv) significantly inhibited inflammation in an in vivo murine model. SX-517 is the first reported boronic acid chemokine antagonist and represents a novel pharmacophore for CXCR1/2 antagonism.

  DOI：

  10.1021/jm500827t

文献信息

• Pyridine- and Pyrimidinecarboxamides as CXCR2 Modulators
  申请人：Maeda Dean Y.

  公开号：US20100210593A1

  公开（公告）日：2010-08-19

  There is disclosed pyridine- and pyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include pyridine- and pyrimidinecarboxamides compounds. More specifically, there is disclosed a genus of CXCR2 inhibitor compounds that are useful for treating a variety of inflammatory and neoplastic disorders.

  披露了作为药物剂的吡啶和嘧啶羧酰胺化合物，合成过程以及包括吡啶和嘧啶羧酰胺化合物的药物组合物。更具体地，披露了一类CXCR2抑制剂化合物，可用于治疗各种炎症和肿瘤性疾病。
• PYRIMIDINECARBOXAMIDES AS CXCR2 MODULATORS
  申请人：SYNTRIX BIOSYSTEMS, INC.

  公开号：US20140206647A1

  公开（公告）日：2014-07-24

  There is disclosed pyridine- and pyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include pyridine- and pyrimidinecarboxamides compounds. More specifically, there is disclosed a genus of CXCR2 inhibitor compounds that are useful for treating a variety of inflammatory and neoplastic disorders.

  本发明公开了吡啶和嘧啶羧酰胺化合物，可用作药物治疗剂，合成过程和包括吡啶和嘧啶羧酰胺化合物的制药组合物。更具体地，本发明公开了一类CXCR2抑制剂化合物，可用于治疗各种炎症和肿瘤性疾病。
• PYRIDINECARBOXAMIDES AS CXCR2 MODULATORS
  申请人：Syntrix Biosystems, Inc.

  公开号：EP2942346B1

  公开（公告）日：2020-05-06
• US8748623B2
  申请人：——

  公开号：US8748623B2

  公开（公告）日：2014-06-10
• US8981106B2
  申请人：——

  公开号：US8981106B2

  公开（公告）日：2015-03-17